24,500 Shares in AxoGen, Inc. $AXGN Purchased by Jupiter Topco LLC

Posted by Francis Steltz on Sep 6th, 2026

Jupiter Topco LLC acquired a new stake in shares of AxoGen, Inc. (NASDAQ:AXGN – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 24,500 shares of the medical equipment provider’s stock, valued at approximately $1,132,000.

A number of other hedge funds also recently bought and sold shares of AXGN. Royal Bank of Canada boosted its holdings in shares of AxoGen by 14.2% during the 1st quarter. Royal Bank of Canada now owns 38,043 shares of the medical equipment provider’s stock worth $704,000 after purchasing an additional 4,723 shares during the last quarter. AQR Capital Management LLC boosted its stake in AxoGen by 45.3% during the first quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider’s stock worth $442,000 after buying an additional 7,453 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in AxoGen by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider’s stock valued at $466,000 after buying an additional 1,057 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in AxoGen by 104,810.0% in the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 10,481 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of AxoGen by 37.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 379,070 shares of the medical equipment provider’s stock worth $4,113,000 after acquiring an additional 103,072 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on AXGN shares. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Truist Financial started coverage on shares of AxoGen in a research report on Wednesday, August 26th. They set a “buy” rating and a $60.00 price objective for the company. HC Wainwright lifted their target price on shares of AxoGen from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a report on Friday, May 29th. Finally, Citizens Jmp increased their price target on shares of AxoGen from $50.00 to $55.00 and gave the company a “market outperform” rating in a research note on Thursday, July 30th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.56.

Read Our Latest Report on AxoGen

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Kathy Weiler sold 14,150 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $45.30, for a total value of $640,995.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph Tyndall sold 3,500 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the sale, the director directly owned 10,650 shares in the company, valued at $529,305. This represents a 24.73% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 98,503 shares of company stock worth $4,656,947. 2.44% of the stock is currently owned by corporate insiders.

AxoGen Stock Up 2.5%

Shares of NASDAQ:AXGN opened at $48.28 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. The firm has a market capitalization of $2.60 billion, a PE ratio of -71.00 and a beta of 1.16. The firm’s 50-day moving average is $45.21 and its two-hundred day moving average is $40.05. AxoGen, Inc. has a 1 year low of $15.27 and a 1 year high of $52.91.

AxoGen (NASDAQ:AXGN – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 EPS for the quarter, meeting the consensus estimate of $0.12. The business had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. Analysts predict that AxoGen, Inc. will post -0.45 EPS for the current year.

AxoGen Company Profile

(Free Report)

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.